Skip to main content

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma

European Journal of Nuclear Medicine and Molecular Imaging volume 40, pages 1836–1842 (2013)Cite this article

Abstract

Purpose

Preoperative identification of aggressiveness is important for the establishment of a treatment strategy in patients with soft-tissue sarcoma (STS). We compared the predictive values of various metabolic parameters derived from PET/CT with 18F-FDG, including maximal standardized uptake value (SUVmax), total lesion glycolysis (TLG) and metabolic tumour volume (MTV).

Methods

A total of 66 patients with STS who had undergone FDG PET/CT before tumour resection were reviewed retrospectively. We determined SUVmax, TLG and MTV to compare their value in predicting disease progression, which was defined as local recurrence and metastases. Receiver operating characteristic curve (ROC) analysis was used to compare the accuracy. Univariate and multivariate analyses of conventional clinicopathological variables were used to compare the reliability of the metabolic parameters.

Results

TLG exhibited greater accuracy than SUVmax or MTV in ROC analysis (area under curve, AUC, 0.802, 0.726 and 0.681, respectively). The cut-off values for disease progression derived from the AUC data were TLG 250; SUVmax 6.0, and MTV 40 cm3. In univariate analysis, TLG (>250) was a more significant predictive factor than SUVmax and MTV (P < 0.001, P = 0.031 and P = 0.022, respectively). TLG was the only meaningful metabolic parameter in the multivariate analysis (P = 0.008) other than presence of metastasis at diagnosis (P = 0.003).

Conclusion

TLG is a more accurate predictor of disease progression than SUVmax or MTV. TLG enables accurate preoperative assessment of aggressiveness comparable with conventional clinicopathological parameters.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi:10.3322/caac.20138.

    PubMed  Article  Google Scholar 

  2. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6.

    PubMed  Article  Google Scholar 

  3. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009;21:345–51. doi:10.1097/CCO.0b013e32832c95e2.

    PubMed  Article  Google Scholar 

  4. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286–94.

    PubMed  Article  Google Scholar 

  5. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–84. doi:10.2967/jnumed.108.053694.

    PubMed  Article  Google Scholar 

  6. Fuglo HM, Jorgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of (18)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39:1416–24. doi:10.1007/s00259-012-2159-z.

    PubMed  Article  CAS  Google Scholar 

  7. Akhurst T, Ng V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, et al. Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer. Clin Positron Imaging. 2000;3:57–65.

    Google Scholar 

  8. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101. doi:10.1016/j.ctrv.2003.07.004.

    PubMed  Article  CAS  Google Scholar 

  9. Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149–54. doi:10.1007/s00259-002-0859-5.

    PubMed  Article  CAS  Google Scholar 

  10. Folpe AL, Lyles RH, Sprouse JT, Conrad 3rd EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279–87.

    PubMed  CAS  Google Scholar 

  11. Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39–49. doi:10.1007/s00259-011-1936-4.

    PubMed  Article  CAS  Google Scholar 

  12. Eary JF, O'Sullivan F, O'Sullivan J, Conrad EU. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J Nucl Med. 2008;49:1973–9. doi:10.2967/jnumed.108.053397.

    PubMed  Article  Google Scholar 

  13. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.

    PubMed  Article  Google Scholar 

  14. Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808–12.

    PubMed  Google Scholar 

  15. Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20:32–40. doi:10.1016/j.acra.2012.07.002.

    PubMed  Article  Google Scholar 

  16. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335–41. doi:10.1016/j.ijrobp.2008.10.060.

    PubMed  Article  Google Scholar 

  17. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966–72. doi:10.1245/s10434-011-2153-x.

    PubMed  Article  Google Scholar 

  18. Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol. 2012;198:1409–16. doi:10.2214/AJR.11.7560.

    PubMed  Article  Google Scholar 

  19. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med. 1999;26:599–605.

    PubMed  Article  CAS  Google Scholar 

  20. Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA. Metastatic myxoid liposarcomas: imaging and histopathologic findings. Skeletal Radiol. 2008;37:251–8. doi:10.1007/s00256-007-0424-1.

    PubMed  Article  Google Scholar 

  21. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66. doi:10.1148/radiol.12111148.

    PubMed  Article  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Affiliations

  1. Department of Orthopaedic Surgery, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul, 110-744, Korea

    Eun-Seok Choi, Han-Soo Kim, Jae Hong Ha & Ilkyu Han

  2. Department of Nuclear Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul, 110-744, Korea

    Seung-Gyun Ha & Jin Chul Paeng

Authors
  1. Eun-Seok Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seung-Gyun Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Han-Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Hong Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin Chul Paeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ilkyu Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jin Chul Paeng or Ilkyu Han.

Additional information

Jin Chul Paeng and Ilkyu Han are both corresponding authors.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Choi, ES., Ha, SG., Kim, HS. et al. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging 40, 1836–1842 (2013). https://doi.org/10.1007/s00259-013-2511-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2511-y

Keywords

  • FDG PET/CT
  • Total lesion glycolysis
  • Standardized uptake value
  • Metabolic tumour volume
  • Soft tissue sarcoma